Literature DB >> 29250256

Natural History of Implantable Cardioverter-Defibrillator Implanted at or after the Age of 70 years in a Veteran Population: A Single Center Study.

Tarek Ajam1,2, Vikas Kalra1,2, Changyu Shen3, Xiaochen Li3, Sandeep Gautam4, Thomas Kambur1,2, Mamta Barmeda5, Kyle W Yancey6, Samer Ajam1,2, Jason Garlie1,2, John M Miller1,2, Rahul Jain1,2.   

Abstract

BACKGROUND: The median age of patients in major Implantable Cardioverter-defibrillator (ICD)trials (MUSTT, MADIT-I, MADIT-II, and SCD-HeFT) was 63-67 years; with only 11% ≥70 years. There is little follow-up data on patients over 70 years of age who received an ICD for primary/secondary prevention of sudden cardiac death, particularly for veterans.
OBJECTIVE: The aim of this study was to study the natural history of ICD implantation for veterans over 70 years of age.
METHODS: We retrospectively reviewed single center ICD data in 216 patients with a mean age at implantation 76 ± 4 years. The ICD indication was primary prevention in 161 patients and secondary prevention in 55 patients. The ICD indication was unavailable in 4 patients.
RESULTS: Mean duration of follow up was 1686 ± 1244 days during which 114 (52%) patients died. Of these, 31% died without receiving any appropriate ICD therapy. Overall, 60/216 (28%) received appropriate therapy and 28/216 (13%) received inappropriate therapy. Patients who had ICD implantation for secondary prophylaxis had statistically more (p= 0.02) appropriate therapies compared to patients who had ICD implantation for primary prevention. Indication for implantation and hypertension predicted appropriate therapy, while age at the time of implantation and presence of atrial fibrillation predicted inappropriate therapies. Overall, 7.7% had device related complications.
CONCLUSIONS: Although 28% septuagenarians in this study received appropriate ICD therapy, they had high rates of mortality, inappropriate therapy, and device complications. ICD implantation in the elderly merits individualized consideration, with higher benefit for secondary prevention.

Entities:  

Year:  2016        PMID: 29250256      PMCID: PMC5673315          DOI: 10.4022/jafib.1496

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  26 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  [Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone].

Authors:  P Della Bella
Journal:  Ital Heart J Suppl       Date:  2000-08

3.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Anant K Vyas; W Jackson Hall; Arthur J Moss; Hongyue Wang; Hua He; Wojciech Zareba; Scott McNitt; Mark L Andrews
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

4.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

5.  Implantable cardiac device procedures in older patients: use and in-hospital outcomes.

Authors:  Jason P Swindle; Michael W Rich; Patrick McCann; Thomas E Burroughs; Paul J Hauptman
Journal:  Arch Intern Med       Date:  2010-04-12

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995.

Authors:  K MacIntyre; S Capewell; S Stewart; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; J J McMurray
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

8.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

9.  Effect of cardiac and noncardiac conditions on survival after defibrillator implantation.

Authors:  Douglas S Lee; Jack V Tu; Peter C Austin; Paul Dorian; Raymond Yee; Alice Chong; David A Alter; Andreas Laupacis
Journal:  J Am Coll Cardiol       Date:  2007-06-11       Impact factor: 24.094

10.  Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.

Authors:  Alfred E Buxton; Kerry L Lee; Gail E Hafley; Luis A Pires; John D Fisher; Michael R Gold; Mark E Josephson; Michael H Lehmann; Eric N Prystowsky
Journal:  J Am Coll Cardiol       Date:  2007-09-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.